Curanex Pharmaceuticals Inc Common Stock cash flow to debt ratio of -3.02K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Curanex Pharmaceuticals Inc Common Stock's free cash flow has decreased 1.79K% from $-555.58K last year to $-10.48M, signaling decreasing performance

Curanex Pharmaceuticals Inc Common Stock's debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability.

Curanex Pharmaceuticals Inc Common Stock has insufficient data to evaluate this check.

Curanex Pharmaceuticals Inc Common Stock has a net cash position, so leverage is healthy.

Curanex Pharmaceuticals Inc Common Stock's interest coverage ratio of 736.38 indicates that earnings with good margin can cover interest payments on company debt

Curanex Pharmaceuticals Inc Common Stock has insufficient data to evaluate this check.

Curanex Pharmaceuticals Inc Common Stock's short-term assets of $11.23M exceed its short-term liabilities of $137.03K

Curanex Pharmaceuticals Inc Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Curanex Pharmaceuticals Inc Common Stock's return on equity of -85.41%, is lower than 15.00%, indicating bad performance

Curanex Pharmaceuticals Inc Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Curanex Pharmaceuticals Inc Common Stock has insufficient public price history to evaluate earnings stability.

Curanex Pharmaceuticals Inc Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it

Curanex Pharmaceuticals Inc Common Stock has negative free cash flow, indicating cash burn

Curanex Pharmaceuticals Inc Common Stock's yearly earnings has decreased 1.07K% since last year from $-361.51K to $-4.23M, signaling decreasing performance

Curanex Pharmaceuticals Inc Common Stock's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -86.83% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Curanex Pharmaceuticals Inc Common Stock's 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Curanex Pharmaceuticals Inc Common Stock has insufficient public price history to evaluate revenue consistency.

Curanex Pharmaceuticals Inc Common Stock has insufficient public price history to evaluate ROE consistency.

Curanex Pharmaceuticals Inc Common Stock has insufficient data to evaluate this check.

Curanex Pharmaceuticals Inc Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Curanex Pharmaceuticals Inc Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Curanex Pharmaceuticals Inc Common Stock has an EV/EBITDA ratio of 10.76x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Curanex Pharmaceuticals Inc Common Stock has insufficient data to evaluate this check.

Curanex Pharmaceuticals Inc Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Curanex Pharmaceuticals Inc Common Stock has a price-to-book ratio of 0.68x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Curanex Pharmaceuticals Inc Common Stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue